Montironi R - Search Results

1

A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.

Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, Wang G, Mazzucchelli R, Bianconi M, Stack EC, Lis R, Patnaik A, Cantley LC, Bubley G, Cordon-Cardo C, Gerald WL, Montironi R, Signoretti S, Loda M, Nardella C, Pandolfi PP. Lunardi A, et al. Among authors: montironi r. Nat Genet. 2013 Jul;45(7):747-55. doi: 10.1038/ng.2650. Epub 2013 Jun 2. Nat Genet. 2013. PMID: 23727860 Free PMC article.

2

Evaluation of prognostic factors in radical prostatectomy specimens with cancer.

Mazzucchelli R, Santinelli A, Lopez-Beltran A, Scarpelli M, Montironi R. Mazzucchelli R, et al. Among authors: montironi r. Urol Int. 2002;68(4):209-15. doi: 10.1159/000058437. Urol Int. 2002. PMID: 12053019 Review.

3

Precancerous lesions and conditions of the prostate: from morphological and biological characterization to chemoprevention.

Montironi R, Mazzucchelli R, Scarpelli M. Montironi R, et al. Ann N Y Acad Sci. 2002 Jun;963:169-84. doi: 10.1111/j.1749-6632.2002.tb04108.x. Ann N Y Acad Sci. 2002. PMID: 12095942

4

Morphological assessment of radical prostatectomy specimens. A protocol with clinical relevance.

Montironi R, Mazzucchelli R, Kwast T. Montironi R, et al. Virchows Arch. 2003 Mar;442(3):211-7. doi: 10.1007/s00428-002-0741-7. Epub 2003 Jan 16. Virchows Arch. 2003. PMID: 12647209 Review.

5

Molecular techniques and prostate cancer diagnostic.

Montironi R, Mazzucchelli R, Scarpelli M. Montironi R, et al. Eur Urol. 2003 Oct;44(4):390-400. doi: 10.1016/s0302-2838(03)00309-9. Eur Urol. 2003. PMID: 14499671 Review.

6

Target populations, pathological biomarkers and chemopreventive agents in prostate cancer prevention.

Montironi R, Barbisan F, Mazzucchelli R. Montironi R, et al. Arch Ital Urol Androl. 2003 Sep;75(3):127-34. Arch Ital Urol Androl. 2003. PMID: 14661390 Review.

7

Androgen ablation therapy for prostate carcinoma suppresses the immunoreactive telomerase subunit hTERT.

Iczkowski KA, Huang W, Mazzucchelli R, Pantazis CG, Stevens GR, Montironi R. Iczkowski KA, et al. Among authors: montironi r. Cancer. 2004 Jan 15;100(2):294-9. doi: 10.1002/cncr.20002. Cancer. 2004. PMID: 14716763 Free article.

8

Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer.

Murphy C, McGurk M, Pettigrew J, Santinelli A, Mazzucchelli R, Johnston PG, Montironi R, Waugh DJ. Murphy C, et al. Among authors: montironi r. Clin Cancer Res. 2005 Jun 1;11(11):4117-27. doi: 10.1158/1078-0432.CCR-04-1518. Clin Cancer Res. 2005. PMID: 15930347

9

Current practice of Gleason grading of prostate carcinoma.

Lopez-Beltran A, Mikuz G, Luque RJ, Mazzucchelli R, Montironi R. Lopez-Beltran A, et al. Among authors: montironi r. Virchows Arch. 2006 Feb;448(2):111-8. doi: 10.1007/s00428-005-0102-4. Epub 2005 Nov 23. Virchows Arch. 2006. PMID: 16328356 Review.

10

2005 update on pathology of prostate biopsies with cancer.

Montironi R, Vela-Navarrete R, Lopez-Beltran A, Mazzucchelli R, Bono A. Montironi R, et al. Eur Urol. 2006 Mar;49(3):441-7. doi: 10.1016/j.eururo.2005.11.022. Epub 2006 Jan 4. Eur Urol. 2006. PMID: 16413665

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,020 results

Search Page

Filters